Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jul:48:34-36.
doi: 10.1016/j.euroneuro.2021.03.023. Epub 2021 Apr 29.

Refining biomarker evaluation in ASD

James C McPartland  1
Affiliations

Refining biomarker evaluation in ASD

James C McPartland. Eur Neuropsychopharmacol. 2021 Jul.

Abstract

This commentary reflects on reasonable biomarker expectations in ASD by addressing three key questions: What is a biomarker? What is required for a biomarker in ASD? How can biomarkers be useful in ASD? In addressing these queries, a path forward emerges based on clear definition of the objective for any given ASD biomarker and evaluation of each biomarker relative to current best practices.

Keywords: Autism spectrum disorder; Biomarkers; Clinical trials; Endpoints.

PubMed Disclaimer

Conflict of interest statement

Declaration of Competing Interest James C. McPartland consults with Customer Value Partners, Bridgebio, and BlackThorn Therapeutics, has received research funding from Janssen Research and Development, serves on the Scientific Advisory Board of Pastorus, and receives royalties from Guilford Press, Lambert, and Springer.

References

    1. Group, F.-N.B.W., 2016-. BEST (Biomarkers, EndpointS, and other Tools) Resource. Jones RM, Carberry C, Hamo A, Lord C, 2017. Placebo-like response in absence of treatment in children with Autism. Autism Research 10, 1567–1572. - PubMed
    1. Key AP, Corbett BA, 2020. The Unfulfilled Promise of the N170 as a Social Biomarker. Biol Psychiatry Cogn Neurosci Neuroimaging 5, 342–353. - PMC - PubMed
    1. McCracken JT, Anagnostou E, Arango C, 2021. Drug Development for Autism Spectrum Disorder (ASD): Progress, Challenges, and Future Directions. European Neuropsychopharmacology. - PMC - PubMed
    1. McPartland J, 2016. Considerations in biomarker development for neurodevelopmental disorders. Curr Opin Neurol 29, 118–122. - PMC - PubMed
    1. McPartland JC, Bernier RA, Jeste SS, Dawson G, Nelson CA, Chawarska K, Earl R, Faja S, Johnson SP, Sikich L, Brandt CA, Dziura JD, Rozenblit L, Hellemann G, Levin AR, Murias M, Naples AJ, Platt ML, Sabatos-DeVito M, Shic F, Senturk D, Sugar CA, Webb SJ, Trials, T.A.B.C.f.C., 2020. The autism biomarkers consortium for clinical trials (ABC-CT): scientific context, study design, and progress toward biomarker qualification. Frontiers in integrative neuroscience 14. - PMC - PubMed

Publication types